Related Experiment Videos
[Hemorheologic therapy of asystematic vertigo].
P Spürk1, H G Dehnert, B Angelkort
1St. Vincenzkrankenhaus, Menden.
VASA. Supplementum
|January 1, 1991
Summary
This study found that additional hemorheological treatment, including lowering hematocrit (hct.), hydroxyethyl starch (HAES), and pentoxifylline, significantly improved outcomes in patients with non-vestibular vertigo compared to risk factor correction alone.
Area of Science:
- Neurology
- Vascular Medicine
- Internal Medicine
Background:
- Vertigo can be associated with hemorheological disturbances and carotid artery atherosclerosis.
- Non-vestibular vertigo requires effective treatment strategies targeting underlying pathologies.
Purpose of the Study:
- To evaluate the efficacy of hemorheological treatment in patients with non-vestibular vertigo.
- To compare outcomes between risk factor correction alone and combined hemorheological therapy.
Main Methods:
- A study involving 88 patients (51 female, 37 male, mean age 65.1) with non-vestibular vertigo.
- Treatment groups included risk factor correction alone versus risk factor correction plus hemorheological interventions (lowering hct., HAES, Pentoxifylline).
Main Results:
- The group receiving additional hemorheological treatment showed a 62% improvement rate.
- The control group (risk factor correction only) had a 35% improvement rate.
- No effect was observed in 25% of the base group, while the hemorheological group had no reported non-responders.
Conclusions:
- Additional hemorheological treatment is more effective than risk factor correction alone for non-vestibular vertigo.
- Hemorheological interventions like lowering hct., HAES, and pentoxifylline offer a promising therapeutic approach.